JP4440481B2 - ＴＮＦ−αにより開始される好中球応答を阻害するためのリポキシン化合物の使用 - Google Patents

ＴＮＦ−αにより開始される好中球応答を阻害するためのリポキシン化合物の使用 Download PDF

Info

Publication number
JP4440481B2
JP4440481B2 JP2000604843A JP2000604843A JP4440481B2 JP 4440481 B2 JP4440481 B2 JP 4440481B2 JP 2000604843 A JP2000604843 A JP 2000604843A JP 2000604843 A JP2000604843 A JP 2000604843A JP 4440481 B2 JP4440481 B2 JP 4440481B2
Authority
JP
Japan
Prior art keywords
carbon atoms
branched
straight
hydrogen atom
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000604843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002539159A (ja
JP2002539159A5 (enExample
Inventor
サーハン，チヤールズ・エヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Brigham and Women's Hospital Inc
Original Assignee
The Brigham and Women's Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham and Women's Hospital Inc filed Critical The Brigham and Women's Hospital Inc
Publication of JP2002539159A publication Critical patent/JP2002539159A/ja
Publication of JP2002539159A5 publication Critical patent/JP2002539159A5/ja
Application granted granted Critical
Publication of JP4440481B2 publication Critical patent/JP4440481B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cephalosporin Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000604843A 1999-03-18 2000-03-14 ＴＮＦ−αにより開始される好中球応答を阻害するためのリポキシン化合物の使用 Expired - Fee Related JP4440481B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12520599P 1999-03-18 1999-03-18
US60/125,205 1999-03-18
PCT/US2000/006582 WO2000054767A1 (en) 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response

Publications (3)

Publication Number Publication Date
JP2002539159A JP2002539159A (ja) 2002-11-19
JP2002539159A5 JP2002539159A5 (enExample) 2006-05-18
JP4440481B2 true JP4440481B2 (ja) 2010-03-24

Family

ID=22418647

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000604843A Expired - Fee Related JP4440481B2 (ja) 1999-03-18 2000-03-14 ＴＮＦ−αにより開始される好中球応答を阻害するためのリポキシン化合物の使用

Country Status (11)

Country Link
US (6) US6387953B1 (enExample)
EP (1) EP1165066B1 (enExample)
JP (1) JP4440481B2 (enExample)
AT (1) ATE310512T1 (enExample)
AU (1) AU775140B2 (enExample)
CA (3) CA2615917C (enExample)
DE (1) DE60024242T2 (enExample)
DK (1) DK1165066T3 (enExample)
ES (1) ES2249257T3 (enExample)
HK (1) HK1043307B (enExample)
WO (1) WO2000054767A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
ES2249257T3 (es) * 1999-03-18 2006-04-01 The Brigham And Women's Hospital, Inc. Utilizacion de compuestos de lipoxina para la inhibicion de la respuesta de los neutrofilos inducida por tnf-alfa.
ES2246230T3 (es) * 1999-03-18 2006-02-16 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina y su utilizacion.
JP4392473B2 (ja) * 1999-03-18 2010-01-06 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ホスホリパーゼｄの活性の調節
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
EP1268393A2 (en) * 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease
GB2362140B (en) * 2000-05-12 2003-03-05 Autoliv Dev Improvements in or relating to an apparatus for a method of folding an air-bag
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
EP1406698B1 (en) * 2001-03-02 2008-10-29 The Brigham and Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis
US6831186B2 (en) 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
CA2465117C (en) * 2001-11-06 2012-01-03 Brigham And Women's Hospital, Inc. Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
EP1911448B1 (en) * 2001-11-06 2013-01-02 The Brigham and Women's Hospital, Inc. Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
CA2467580C (en) * 2001-12-18 2012-10-30 Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
DK2216318T3 (en) * 2002-08-12 2018-12-10 Brigham & Womens Hospital Resolvins: Bio templates for therapeutic interventions
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
DK1720893T3 (en) 2004-02-26 2014-11-24 Baylor Res Inst COMPOSITIONS AND PROCEDURES FOR THE SYSTEMIC TREATMENT OF ARTHRITIS
EP1755537A4 (en) * 2004-04-14 2009-12-09 Univ Boston METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
WO2007061783A1 (en) * 2005-11-18 2007-05-31 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
US7906678B2 (en) 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
US20120220658A1 (en) * 2009-10-21 2012-08-30 University Of Medicine And Dentistry Of New Jersey Method for Treating Sepsis or Septic Shock
US11519911B2 (en) 2017-01-31 2022-12-06 The Brigham And Women's Hospital, Inc. ALX receptor ligands define a biochemical endotype for inflammation-based diseases
CA3114750A1 (en) 2018-10-09 2020-04-16 University Of Rochester Treatment of vulvovaginal disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048897A (en) * 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) * 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
EP0703897B1 (en) * 1993-06-15 2008-08-20 The Brigham And Women's Hospital, Inc. Lipoxin compounds with prolonged half-life
WO1995001179A1 (en) 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
JP4392473B2 (ja) * 1999-03-18 2010-01-06 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ホスホリパーゼｄの活性の調節
ES2246230T3 (es) * 1999-03-18 2006-02-16 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina y su utilizacion.
ES2249257T3 (es) * 1999-03-18 2006-04-01 The Brigham And Women's Hospital, Inc. Utilizacion de compuestos de lipoxina para la inhibicion de la respuesta de los neutrofilos inducida por tnf-alfa.

Also Published As

Publication number Publication date
US20080081838A1 (en) 2008-04-03
US20040192785A1 (en) 2004-09-30
US7132451B2 (en) 2006-11-07
CA2367909C (en) 2008-02-12
US20020143069A1 (en) 2002-10-03
US20080312323A1 (en) 2008-12-18
US6710084B2 (en) 2004-03-23
ATE310512T1 (de) 2005-12-15
US20020132847A1 (en) 2002-09-19
JP2002539159A (ja) 2002-11-19
DE60024242T2 (de) 2006-12-14
US6703423B2 (en) 2004-03-09
DK1165066T3 (da) 2006-03-06
CA2615917A1 (en) 2000-09-21
CA2367909A1 (en) 2000-09-21
DE60024242D1 (de) 2005-12-29
ES2249257T3 (es) 2006-04-01
EP1165066B1 (en) 2005-11-23
CA2615917C (en) 2011-10-04
WO2000054767A1 (en) 2000-09-21
HK1043307A1 (en) 2002-09-13
EP1165066A1 (en) 2002-01-02
US6387953B1 (en) 2002-05-14
CA2747376A1 (en) 2000-09-21
AU775140B2 (en) 2004-07-22
HK1043307B (en) 2006-02-03
AU3880600A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
US20080081838A1 (en) Inhibition of TNF-alpha-Initiated Neutrophil Response
AU2008216965B9 (en) Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US7994219B2 (en) Approach to anti-microbial host defense with molecular shields with lipoxin compounds
JP2002539181A (ja) リポキシン化合物およびこれらの使用
AU2007214312B2 (en) Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response
AU2004222825B2 (en) Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response
EP1616566A1 (en) Lipoxin compounds for treating TNF-alpha initiated inflammation
HK1078497A (en) Lipoxin compounds for treating tnf-alpha initiated inflammation
EP1911448B1 (en) Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
AU2012203640A1 (en) Lipoxins and Asprin-Triggered Lipoxins and their Stable Analogs in the Treatment of Asthma and Inflammatory Airway Diseases
AU2002352553A1 (en) Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20070208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070507

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070806

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090610

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091208

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100107

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130115

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130115

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees